Accessibility Menu
bioMérieux logo

bioMérieux(OTC) BMXMF

Market Cap$9.30BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2004)+117%
5 Year-31%
1 Year-45%
1 Month-5%
$82.66
+0.00%
+0.00Today
bioMérieux last closing stock price
MetricPriceDate
Last closeUSD 78.992026-08-06
bioMérieux stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 78.992026-07-23
1 month-4.58%USD 82.782026-07-07
3 month-6.43%USD 84.422026-05-07
Year to date-38.89%USD 129.252025-12-30
1 year-45.22%USD 144.202025-08-05
3 year-25.32%USD 105.772023-07-28
5 year-31.02%USD 114.512021-08-06
Since inception+117.45%USD 36.322004-07-22

bioMérieux Financials at a Glance

Market Cap

$9.30BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€8.11B

Net Income (TTM)

€839.87M

EPS (TTM)

$4.55

P/E Ratio

17.26

Dividend

$1.13

Beta (Volatility)

0.26 (Low)

Price

$82.66

Volume

4

Open

$82.66

Previous Close

$78.99

Daily Range

$82.66 - $82.66

52-Week Range

$77.00 - $152.00

Estimated Earnings Date

Mar 4, 2027

BMXMF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About bioMérieux

bioMérieux S.A. is a global leader in in vitro diagnostic solutions, specializing in the detection of infectious diseases, cardiovascular conditions, and various cancers. Founded in 1963 and headquartered in Marcy l'Etoile, France, the company serves a diverse clientele, including clinical laboratories, medical professionals, and industrial control facilities.

Products and Services
  • In vitro diagnostic systems for infectious diseases
  • Microbiological testing for food and pharmaceutical industries
  • Diagnostic solutions for cardiovascular and cancer detection
Growth Outlook
  • Revenue growth of 9.5% year-over-year in Q2 2026
  • Strong demand for diagnostic solutions in emerging markets
  • Investment in R&D to enhance product offerings and innovation
Financial Highlights
  • Net income of €225.76 million in Q2 2026
  • Operating income margin of 15.23% in the latest quarter
  • TTM revenue of €7.84 billion, reflecting consistent growth
bioMérieux S.A. operates in the healthcare sector, focusing on medical diagnostics and research. The company has demonstrated robust financial performance, with a net income of €225.76 million reported in the second quarter of 2026. This reflects a solid operating income margin of 15.23%, indicating effective cost management and operational efficiency. The trailing twelve-month revenue of €7.84 billion showcases the company's ability to maintain consistent growth in a competitive market. The company’s commitment to research and development is evident, with significant investments aimed at enhancing its product offerings. This focus on innovation, combined with a growing demand for diagnostic solutions, particularly in emerging markets, positions bioMérieux S.A. favorably for future growth. The recent revenue growth of 9.5% year-over-year in Q2 2026 further underscores the company's strong market presence and potential for continued success.
AI Generated • Jul 31, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

15,078

CEO

Pierre Boulud

Website

www.biomerieux.com

Headquarters

Marcy l'Étoile, ARA 69280, FR

BMXMF Financials

Key Financial Metrics (TTM)

Gross Margin

52.04%

Operating Margin

11.99%

Net Income Margin

11.59%

Return on Equity

11.01%

Return on Capital

14.35%

Return on Assets

8.12%

Earnings Yield

5.79%

Dividend Yield

1.43%

Payout Ratio

24.91%

Stock Overview

Market Cap

$9.30BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

117.69M

Volume

4

Avg. Volume

212.873

Financials (TTM)

Gross Profit

€4.39B

Operating Income

€987.49M

EBITDA

€1.89B

Operating Cash Flow

€1.69B

Capital Expenditure

-€670.12M

Free Cash Flow

€1.02B

Cash & ST Invst.

€656.72M

Total Debt

€421.17M

bioMérieux Performance Analysis

bioMérieux annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 3,772,051,920-5.5%
20232023-12-31EUR 3,972,775,5065.3%
20242024-12-31EUR 4,305,021,0418.4%
20252025-12-31EUR 4,593,086,5436.7%
bioMérieux sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-319.3%
Q22025-06-30-1.6%
Q42025-12-31-0.9%
Q22026-06-30-3.1%
bioMérieux annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR 4.01-32.8%
20232023-12-31EUR 3.25-18.9%
20242024-12-31EUR 3.9421.0%
20252025-12-31EUR 3.77-4.1%
bioMérieux sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31N/A
Q22025-06-30-25.8%
Q42025-12-3146.7%
Q22026-06-30-3.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

€1.96B

+3.1%

Gross Profit

€1.08B

+1.8%

Gross Margin

55.18%

N/A

Market Cap

$9.30BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$616.56K

N/A

Employees

15,078

N/A

Net Income

€225.76M

+4.9%

EBITDA

€440.54M

+10.2%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

€656.72M

+141.3%

Total Debt

€421.17M

-24.6%

Accounts Receivable

€960.66M

+38.2%

Inventory

€973.84M

-3.8%

Long Term Debt

€188.32M

-49.6%

Short Term Debt

€232.85M

+25.8%

Return on Assets

8.12%

N/A

Return on Invested Capital

10.48%

N/A

Free Cash Flow

€296.85M

+533.0%

Operating Cash Flow

€436.15M

+121.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TWSTTwist Bioscience Corporation
$120.39-3.91%
ICLRICON Public Limited Company
$163.38-2.45%
CRLCharles River Laboratories International, Inc.
$276.89-1.56%
CDNACareDx, Inc
$45.57-3.82%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$15.21+0.09%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.60-0.00%
ONDSOndas
$9.20+0.03%
INTCIntel
$103.10-0.01%

Questions About BMXMF

What is the current price of bioMérieux?

bioMérieux is trading at $82.66 per share.

What is the 52-week range for bioMérieux?

Over the past 52 weeks, bioMérieux has traded between $77.00 and $152.00.

How much debt does bioMérieux have?

As of the most recent reporting period, bioMérieux reported total debt of €541.89M.

How much cash does bioMérieux have on hand?

bioMérieux reported €669.20M in cash and cash equivalents in its most recent financial results.

What is bioMérieux’s dividend yield?

bioMérieux currently has a dividend yield of 1.43%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services